Bio-Rad Laboratories, Inc. (NYSE:BIO) Stake Raised by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 14.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 746,119 shares of the medical research company's stock after buying an additional 91,690 shares during the period. Dimensional Fund Advisors LP owned 2.66% of Bio-Rad Laboratories worth $245,106,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Bio-Rad Laboratories by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 1,919,808 shares of the medical research company's stock valued at $630,676,000 after buying an additional 12,168 shares during the last quarter. Wealthfront Advisers LLC bought a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at approximately $342,686,000. Sei Investments Co. raised its holdings in shares of Bio-Rad Laboratories by 7.5% during the fourth quarter. Sei Investments Co. now owns 271,387 shares of the medical research company's stock valued at $89,156,000 after buying an additional 18,873 shares during the last quarter. Mawer Investment Management Ltd. raised its holdings in shares of Bio-Rad Laboratories by 17.9% during the fourth quarter. Mawer Investment Management Ltd. now owns 256,927 shares of the medical research company's stock valued at $84,403,000 after buying an additional 39,042 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Bio-Rad Laboratories by 4.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 191,867 shares of the medical research company's stock worth $63,030,000 after purchasing an additional 7,552 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Royal Bank of Canada restated an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company cut their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of "Moderate Buy" and an average target price of $380.20.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO traded down $7.52 during trading on Friday, hitting $242.22. The company had a trading volume of 377,689 shares, compared to its average volume of 317,205. The company has a market cap of $6.78 billion, a P/E ratio of -3.72 and a beta of 1.12. Bio-Rad Laboratories, Inc. has a 52 week low of $215.38 and a 52 week high of $387.99. The business's 50-day moving average is $251.03 and its 200 day moving average is $308.11. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.